Studies at ASCO Point to Biomarker-Directed Treatment for Colorectal Cancer
At the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, several research studies were presented that shared a targeted approach to colorectal cancer (CRC) treatment that can ensure efficacy and reduction of side effects. The infographic below highlights those studies and their key findings.
Left column:
Right column:
- Clinical and molecular characterization of fusion genes in colorectal cancer.
- Development and validation of an individualized immune prognostic signature in colorectal cancer.
- Metagenomic analysis of the fecal microbiome in patients with colorectal cancer compared to healthy controls as a function of age.
Leave a Reply
Want to join the discussion?Feel free to contribute!